BioVersys, a Switzerland-based multi-asset, clinical stage biopharmaceutical company focusing on R&D of novel antibacterial products, has priced its IPO at CHF36 per share, implying a market cap of CHF213m (US$235m)….
Switzerland: BioVersys shares begin trading on SIX Swiss
…
…






